Autopsy report · NCT01499251
Clinical Study on the Safety and Tolerability of Macitentan in Combination With Dose-dense Temozolomide in Patients With Recurrent Glioblastoma
Cause of deathFutility
“Results did not clearly support continuing development in recurrent GBM”
Life of this trial
- Ran for about 4 years 3 months before it stopped.
- 75 participants planned (an estimate, not an actual count).
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 1
- Sponsor
- Actelion
- Sponsor type
- Industry
- Conditions
- Glioblastoma
- Interventions
- Phase 1 Dose Escalation; Phase 1b; Ancillary Study
- Participants
- 75 (planned, not actual)
- Sites
- 1
- Countries
- United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.